Chemotherapy in the treatment of metastatic prostate cancer: the present state of the problem

B Ya Alekseev

doi:10.17650/1726-9776-2015-11-3-108-116

Abstract

The paper reviews the current possibilities of cytostatic chemotherapy in patients with metastatic prostate cancer. It gives the data of studies dealing with the early use of docetaxel in patents with hormone-susceptible tumors and analyzes approaches to sequential therapy with docetaxel, cabazitaxel, and antiandrogens (abiraterone, enzalutamide) in patients with castration-refractory prostate cancer. Assessment of the prognostic role of different clinical and biological factors could provide an algorithm for the choice of first- and second-line therapy in patients with castration resistance.

Highlights

Chemotherapy in the treatment of metastatic prostate cancer: the present state of the problem B.Ya
Lopatkin Scientific Research Institute of Urology and Interventional Radiology – branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation; 4 Bldg, 51, 3erd Parkovaya St., Moscow, 105425, Russia The paper reviews the current possibilities of cytostatic chemotherapy in patients with metastatic prostate cancer
It gives the data of studies dealing with the early use of docetaxel in patents with hormone-susceptible tumors and analyzes approaches to sequential therapy with docetaxel, cabazitaxel, and antiandrogens in patients with castration-refractory prostate cancer

Summary

Introduction

Chemotherapy in the treatment of metastatic prostate cancer: the present state of the problem B.Ya. В группе доцетаксела достигнуто увеличение медианы времени до развития кастрационной резистентности до 20,2 мес по сравнению 11,7 мес в группе АДТ (р < 0,001), а частота снижения уровня ПСА < 0,2 нг/мл через 12 мес после начала лечения (наиболее сильный предиктор выживаемости) составила в группах комбинированного и гормонального лечения 27,7 и 16,8 % соответственно (р < 0,001).

Results

Conclusion